李代蓉1 杨燕青2 黄新华2.ERCC1 多态性与肺癌铂类化疗耐药的关系研究[J].现代生物医学进展英文版,2011,11(3):519-522. |
ERCC1 多态性与肺癌铂类化疗耐药的关系研究 |
Correlation of excision repair cross-complementing gene1 polymorphismsand platinum chemotherapy resistance of lung cancer |
|
DOI: |
中文关键词: DNA切除修复交叉互补基因1 非小细胞肺癌 化疗 药物敏感性 |
英文关键词: excision repair cross-complementing gene1 non small cell lung cancer sensitivity chemotherapy |
基金项目:重庆市卫生局科研基金(编号07-2-180) |
|
Hits: 770 |
Download times: 881 |
中文摘要: |
目的:研究DNA 切除修复交叉互补基因1(excision repair cross-complementing gene1,ERCC1)单核苷酸多态性与非小细胞
肺癌铂类药物化疗敏感性的关系。方法:应用基因测序方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC1
Asn118Asn基因型,,比较不同基因型与化疗疗效的关系。结果:89例患者化疗总有效率为29.2%。携带ERCC1 CC基因型、含至
少一个变异基因型(TC 和TT 基因型)患者的有效率分别为38.5%和61.5%(X2=2.151,p=0.142),基因型在化疗有效组和无效组之
间的分布无差异(p>0.05)。结论:ERCC1 Asn118Asn单核苷酸多态性可能与非小细胞肺癌对铂类药物化疗的敏感性无关。 |
英文摘要: |
Objective: To investigate the relationship between ERCC1 single nucleotide polymorphisms and sensitivity to Platinum
-based chemotherapy among patients with advanced non small cell lung cancer. Methods: We used gene sequencing analysis to determine
the single nucleotide polymorphisms (SNPs) i of excision repair cross-complementing gene1 (ERCC1)in DNA from peripheral
lymphocytes. Totally 89 patients with NSCLC were treated with Platinum -based chemotherapy, and clinical response was evaluated after
2 cycles. The association between ERCC1 gene polymorphisms and chemosensitivity were analyzed. Results: The overall response rate
was 29.2. The verall response rate of ERCC1 CC genotypes and TT/CT genotypes were 38.5%and 61.5%(X2=2.151,p=0.142). Chemotherapy
response did not show statistically significant differences between the wild genotypes and the variant genotypes for the ERCC1 gene
(38.5%vs61.5%,X2=2.151,p=0.142). Conclusion: ERCC1 Asn118Asn SNP may be not associated with sensitivity to plat- inum-based
chemotherapy in NSCLC patients. |
View Full Text
View/Add Comment Download reader |
Close |